Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Genfleet Therapeutics / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/genfleet-therapeutics-shanghai-inc-class-h" target="_blank" data-smartkarma-citation="entities:44187:1" rel="noopener">Genfleet Therapeutics (2595 HK)</a> announced the placement of 13.6M shares for subscription at HK$ 34.69 per share. The placing price represents a discount of 9.7% to the undisturbed price.</li>
<li>Genfleet Therapeutics intends to use the proceeds majorly to advance core products of RAS inhibitors and other innovative treatments, enhance company’s research and development platforms and for working capital.</li>
<li>Genfleet is rightly placed at this point to accelerate the clinical development of core products, rapidly advance their innovative product pipeline to later stages of development and expand the portfolio.</li>
</ul>



Genfleet Therapeutics (2595 HK) announced the placement of 13.6M shares for subscription at HK$ 34.69 per share. The placing price represents a discount of 9.7% to the undisturbed price.
Genfleet Therapeutics intends to use the proceeds majorly to advance core products of RAS inhibitors and other innovative treatments, enhance company’s research and development platforms and for working capital.
Genfleet is rightly placed at this point to accelerate the clinical development of core products, rapidly advance their innovative product pipeline to later stages of development and expand the portfolio.


Genfleet Therapeutics (2595 HK) Placement: RAS Portfolio Offerings To Deliver Strength